State cancer agency finds new oncogenic drug target
A research team at the National Cancer Center (NCC) Graduate School of Cancer Science and Policy has uncovered new drug targets that can simultaneously control multiple oncogenes.
The main reason for developing cancer is due to the overexpression of various oncogenes. Targeted anticancer drugs used in clinical trials mostly aim one or two oncogenes, so the treatment cannot cure cancer that grows by depending on other carcinogenic genes than the target. Genetic information on the nucleus chromosome is transferred to messenger ribonucleic acid (mRNA), and mRNA then crosses the nuclear membrane and travels to the protein synthesis plant in the cytosol.
The research team, led by Professors Lee Byung-il and Jang Hyon-chol, found that a protein complex called Apoptosis inhibitor 5 (API5) and Fibroblast Growth Factor 2 (FGF2) plays a crucial role in controlling mRNA migration of essential carcinogenic genes such as c-Myc and Cyclin D1 (CCND1).